x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012370
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu504 of human OMA1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | OMA1 |
| UniProt No. | Q96E52 |
| Gene ID | 115209 |
| Gene Description | Mitochondria continuously divide and fuse. This dynamic process is highly regulated in response to various physiological cues. The GTPase OPA1 mediates the fusion of the mitochondrial inner membrane. Constitutive proteolytic processes mediated by OMA1 and YME1L convert long isoforms into short isforms. The balance between L-OPA1 and S-OPA1 is required to maintain a normal morphology of mitochondria.OMA1 is synthesized as a precursor and processed into a mature form. OMA1 is constitutively active and cleaves L-OPA1 at the S1 site. However, various stress stimuli can further activate OMA1 and result in the rapid and complete conversion of L-OPA1 into S-OPA1, which inhibits fusion and causes mitochondrial fragmentation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
